Search Results

The state AGs sent a letter to Senate and House leaders, highlighting the urgent need for federal action to mandate that pharmacy benefit managers increase transparency into their practices by sharing pricing with health plans.

Concerns that the mergers raise consumer prices and reduce access to health care have sparked the state-level scrutiny, as the FTC has been slowing the rapid pace of acquisitions and consolidations at the federal level.

President Biden's battle against high drug prices, part of the Inflation Reduction Act, is intended to give Medicare patients immediate relief and, in the long term, to regulate what drugmakers charge for their products.

Join this complimentary webcast to gain invaluable insights in supporting high-cost, highly-complex conditions that exist in all employer plans today.

Joing this webcast as we explore three critical elements to help future-proof your practice in our evolving remote legal landscape: agility, breadth of service and security.

The new state regulations are aimed at increased transparency to consumers and employers, as well as rooting out spread-pricing, which enables PBMs to charge pharmacists higher prices than they pay to manufacturers.

The state plans to invest $6.5 million in funds from the 2021 American Rescue Plan Act toward a partnership with nonprofit RIP Medical Debt, which buys bundled medical debt portfolios from providers.

Though J&J is one of the country's largest drugmakers, the lawsuit argues, it failed to use its buying power when purchasing medications to negotiate the best prices for medicines for workers on its health plan.